View Future GrowthOvation Science 과거 순이익 실적과거 기준 점검 0/6Ovation Science은 연평균 27.5%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 8.5%의 비율로 증가했습니다. 매출은 연평균 41.8%의 비율로 감소했습니다.핵심 정보27.48%순이익 성장률31.11%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률7.33%매출 성장률-41.82%자기자본이익률n/a순이익률-936.47%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 26First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (in line with 1Q 2025). Revenue: CA$15.4k (down 12% from 1Q 2025). Net loss: CA$106.6k (loss narrowed 12% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 30Second quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.009 loss in 2Q 2023)Second quarter 2024 results: CA$0.003 loss per share (improved from CA$0.009 loss in 2Q 2023). Revenue: CA$42.2k (up CA$40.2k from 2Q 2023). Net loss: CA$75.8k (loss narrowed 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.Reported Earnings • May 07Full year 2023 earnings released: CA$0.027 loss per share (vs CA$0.027 loss in FY 2022)Full year 2023 results: CA$0.027 loss per share (in line with FY 2022). Revenue: CA$61.9k (down 55% from FY 2022). Net loss: CA$813.1k (loss widened 2.4% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 29Third quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 3Q 2022)Third quarter 2023 results: CA$0.007 loss per share (in line with 3Q 2022). Revenue: CA$4.4k (down 87% from 3Q 2022). Net loss: CA$193.2k (loss narrowed 2.8% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 03Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)Second quarter 2023 results: CA$0.009 loss per share (further deteriorated from CA$0.007 loss in 2Q 2022). Revenue: CA$2.0k (down 93% from 2Q 2022). Net loss: CA$262.0k (loss widened 22% from 2Q 2022).Reported Earnings • May 07Full year 2022 earnings released: CA$0.027 loss per share (vs CA$0.081 loss in FY 2021)Full year 2022 results: CA$0.027 loss per share (improved from CA$0.081 loss in FY 2021). Revenue: CA$138.2k (down 39% from FY 2021). Net loss: CA$794.1k (loss narrowed 67% from FY 2021).모든 업데이트 보기Recent updatesReported Earnings • May 26First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (in line with 1Q 2025). Revenue: CA$15.4k (down 12% from 1Q 2025). Net loss: CA$106.6k (loss narrowed 12% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.공시 • Oct 21Ovation Science Inc. announced that it has received CAD 0.15835 million in fundingOn October 20, 2025, Ovation Science Inc closed the transaction. The company issued 3,167,000 units at a price of CAD 0.05 per unit for aggregate gross proceeds of CAD 158,350. A director of the company participated in the transaction and acquired 200,000 units. This participation is considered a related party transaction under MI 61-101 but is exempt from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(b) and 5.7(1)(b), as the value of the transaction is less than 25 per cent of the company's market capitalization. In connection with the offering, the company paid eligible finders a cash fee equal to 8 per cent of the gross proceeds raised from investors they introduced.공시 • Sep 30Ovation Science Inc. announced that it expects to receive CAD 0.2 million in fundingOvation Science Inc. announced a non-brokered private placement financing of 4,000,000 units at a price of CAD 0.05 per Unit for proceeds of CAD 200,000 on September 29, 2025. Under the Offering, each unit will consist of one common share and one share purchase warrant. Each Warrant will entitle the holder to purchase an additional share at a price of CAD 0.05 per share for a period of 24 months from the date of issue. The Units issued under the Offering will be subject to a statutory hold period of four months and one day from the date of issuance. In connection with the Offering, the Company will pay eligible finders a fee in cash equal to 8% of the gross proceeds raised from persons introduced by the Finder and/or share purchase warrants equal to 8% of the total number of Units subscribed for by persons introduced by the Finder. The broker’s warrants will be exercisable to purchase an additional share at CAD 0.05 per share for a period of 24 months from the date of issue.공시 • Sep 29Ovation Science Inc., Annual General Meeting, Nov 25, 2025Ovation Science Inc., Annual General Meeting, Nov 25, 2025.Reported Earnings • Aug 30Second quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.009 loss in 2Q 2023)Second quarter 2024 results: CA$0.003 loss per share (improved from CA$0.009 loss in 2Q 2023). Revenue: CA$42.2k (up CA$40.2k from 2Q 2023). Net loss: CA$75.8k (loss narrowed 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.Board Change • Aug 15Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Joan Chypyha was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Jul 23Ovation Science Inc., Annual General Meeting, Sep 20, 2024Ovation Science Inc., Annual General Meeting, Sep 20, 2024.Reported Earnings • May 07Full year 2023 earnings released: CA$0.027 loss per share (vs CA$0.027 loss in FY 2022)Full year 2023 results: CA$0.027 loss per share (in line with FY 2022). Revenue: CA$61.9k (down 55% from FY 2022). Net loss: CA$813.1k (loss widened 2.4% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.공시 • Apr 12Ovation Science Inc. announced that it has received $0.05 million in fundingOn April 11, 2024, Ovation Science Inc closed the transaction.공시 • Mar 21Ovation Science Inc. announced that it expects to receive CAD 0.0675 million in fundingOvation Science Inc. announced a private placement of 1,350,000 Units at a price of CAD 0.05 per Unit for a gross proceeds of CAD 67,500 on March 20, 2024. Each unit consists of one common share of the Company and one non-transferable share purchase warrant. Each warrant is exercisable to purchase an additional common share at a price of CAD 0.05 per share for a period of 24 months from closing of the private placement. The securities issued under the private placement will be subject to a hold period expiring four months and one day from the date of issuance pursuant to applicable Canadian securities laws and relevant restrictions under the securities laws of other jurisdictions where the placees may be residents.Reported Earnings • Nov 29Third quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 3Q 2022)Third quarter 2023 results: CA$0.007 loss per share (in line with 3Q 2022). Revenue: CA$4.4k (down 87% from 3Q 2022). Net loss: CA$193.2k (loss narrowed 2.8% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.New Risk • Oct 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (78% average weekly change). Negative equity (-CA$502k). Earnings have declined by 19% per year over the past 5 years. Revenue is less than US$1m (CA$113k revenue, or US$83k). Market cap is less than US$10m (€1.09m market cap, or US$1.15m). Minor Risk Shareholders have been diluted in the past year (6.8% increase in shares outstanding).공시 • Oct 13Ovation Science Inc. announced that it has received CAD 0.2 million in fundingOn October 12, 2023, Ovation Science Inc. closed the transaction. Net proceeds of the offering are CAD 184,000 after payment of commissions totaling CAD 16,000. The Company issued a total of 480,000 brokers warrants.공시 • Oct 05Ovation Science Inc. announced that it expects to receive CAD 0.2 million in fundingOvation Science Inc. announced a proposed private placement of up to 4,000,000 units at a price of CAD 0.05 per unit for the gross proceeds of CAD 200,000 on October 3, 2023. Each Unit consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase an additional share at a price of CAD 0.05 per share for a two-year term. The Company will pay a commission of 8% cash and 480,000 broker warrants in connection with this offering.Reported Earnings • Sep 03Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)Second quarter 2023 results: CA$0.009 loss per share (further deteriorated from CA$0.007 loss in 2Q 2022). Revenue: CA$2.0k (down 93% from 2Q 2022). Net loss: CA$262.0k (loss widened 22% from 2Q 2022).공시 • Jun 21Ovation Science Inc., Annual General Meeting, Aug 22, 2023Ovation Science Inc., Annual General Meeting, Aug 22, 2023.Reported Earnings • May 07Full year 2022 earnings released: CA$0.027 loss per share (vs CA$0.081 loss in FY 2021)Full year 2022 results: CA$0.027 loss per share (improved from CA$0.081 loss in FY 2021). Revenue: CA$138.2k (down 39% from FY 2021). Net loss: CA$794.1k (loss narrowed 67% from FY 2021).Reported Earnings • Nov 30Third quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 3Q 2021)Third quarter 2022 results: CA$0.007 loss per share (in line with 3Q 2021). Revenue: CA$34.5k (down 1.1% from 3Q 2021). Net loss: CA$198.8k (loss narrowed 1.9% from 3Q 2021).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 28Second quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2021)Second quarter 2022 results: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2021). Revenue: CA$29.5k (down 61% from 2Q 2021). Net loss: CA$214.3k (loss widened 4.7% from 2Q 2021).Reported Earnings • May 04Full year 2021 earnings released: CA$0.081 loss per share (vs CA$0.044 loss in FY 2020)Full year 2021 results: CA$0.081 loss per share (down from CA$0.044 loss in FY 2020). Revenue: CA$224.9k (down 70% from FY 2020). Net loss: CA$2.39m (loss widened 102% from FY 2020).Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 28Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: CA$0.007 loss per share (up from CA$0.01 loss in 3Q 2020). Revenue: CA$34.9k (down 81% from 3Q 2020). Net loss: CA$202.6k (loss narrowed 20% from 3Q 2020). Revenue was in line with analyst estimates.Reported Earnings • Sep 02Second quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.025 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: CA$76.3k (down 24% from 2Q 2020). Net loss: CA$204.7k (loss narrowed 67% from 2Q 2020).Reported Earnings • Jun 03First quarter 2021 earnings released: CA$0.006 loss per share (vs CA$0.005 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: CA$73.5k (down 75% from 1Q 2020). Net loss: CA$161.4k (loss widened 46% from 1Q 2020).Reported Earnings • May 02Full year 2020 earnings released: CA$0.044 loss per share (vs CA$0.052 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: CA$750.0k (up 148% from FY 2019). Net loss: CA$1.18m (loss widened 42% from FY 2019).Reported Earnings • Dec 02Third quarter 2020 earnings released: CA$0.01 loss per shareThe company reported a solid third quarter result with improved revenues and control over expenses, though losses increased. Third quarter 2020 results: Revenue: CA$181.0k (up 129% from 3Q 2019). Net loss: CA$253.8k (loss widened 80% from 3Q 2019).매출 및 비용 세부 내역Ovation Science가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:0VH 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Mar 260-11031 Dec 250-11030 Sep 25000030 Jun 25000031 Mar 25001031 Dec 24001030 Sep 240-11030 Jun 240-11031 Mar 240-11031 Dec 230-11030 Sep 230-11030 Jun 230-11031 Mar 230-11031 Dec 220-11030 Sep 220-21030 Jun 220-21031 Mar 220-21031 Dec 210-21030 Sep 210-11030 Jun 210-11031 Mar 211-11031 Dec 201-11030 Sep 201-11030 Jun 201-11031 Mar 201-11031 Dec 190-11030 Sep 190-11030 Jun 190-11031 Mar 190-11031 Dec 180-10031 Dec 170000양질의 수익: 0VH 은(는) 현재 수익성이 없습니다.이익 마진 증가: 0VH는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 0VH는 수익성이 없지만 지난 5년 동안 연평균 27.5%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 0VH의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 0VH은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(15.1%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 0VH의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/29 15:04종가2026/06/26 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Ovation Science Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 26First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (in line with 1Q 2025). Revenue: CA$15.4k (down 12% from 1Q 2025). Net loss: CA$106.6k (loss narrowed 12% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 30Second quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.009 loss in 2Q 2023)Second quarter 2024 results: CA$0.003 loss per share (improved from CA$0.009 loss in 2Q 2023). Revenue: CA$42.2k (up CA$40.2k from 2Q 2023). Net loss: CA$75.8k (loss narrowed 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.
Reported Earnings • May 07Full year 2023 earnings released: CA$0.027 loss per share (vs CA$0.027 loss in FY 2022)Full year 2023 results: CA$0.027 loss per share (in line with FY 2022). Revenue: CA$61.9k (down 55% from FY 2022). Net loss: CA$813.1k (loss widened 2.4% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 29Third quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 3Q 2022)Third quarter 2023 results: CA$0.007 loss per share (in line with 3Q 2022). Revenue: CA$4.4k (down 87% from 3Q 2022). Net loss: CA$193.2k (loss narrowed 2.8% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 03Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)Second quarter 2023 results: CA$0.009 loss per share (further deteriorated from CA$0.007 loss in 2Q 2022). Revenue: CA$2.0k (down 93% from 2Q 2022). Net loss: CA$262.0k (loss widened 22% from 2Q 2022).
Reported Earnings • May 07Full year 2022 earnings released: CA$0.027 loss per share (vs CA$0.081 loss in FY 2021)Full year 2022 results: CA$0.027 loss per share (improved from CA$0.081 loss in FY 2021). Revenue: CA$138.2k (down 39% from FY 2021). Net loss: CA$794.1k (loss narrowed 67% from FY 2021).
Reported Earnings • May 26First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (in line with 1Q 2025). Revenue: CA$15.4k (down 12% from 1Q 2025). Net loss: CA$106.6k (loss narrowed 12% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
공시 • Oct 21Ovation Science Inc. announced that it has received CAD 0.15835 million in fundingOn October 20, 2025, Ovation Science Inc closed the transaction. The company issued 3,167,000 units at a price of CAD 0.05 per unit for aggregate gross proceeds of CAD 158,350. A director of the company participated in the transaction and acquired 200,000 units. This participation is considered a related party transaction under MI 61-101 but is exempt from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(b) and 5.7(1)(b), as the value of the transaction is less than 25 per cent of the company's market capitalization. In connection with the offering, the company paid eligible finders a cash fee equal to 8 per cent of the gross proceeds raised from investors they introduced.
공시 • Sep 30Ovation Science Inc. announced that it expects to receive CAD 0.2 million in fundingOvation Science Inc. announced a non-brokered private placement financing of 4,000,000 units at a price of CAD 0.05 per Unit for proceeds of CAD 200,000 on September 29, 2025. Under the Offering, each unit will consist of one common share and one share purchase warrant. Each Warrant will entitle the holder to purchase an additional share at a price of CAD 0.05 per share for a period of 24 months from the date of issue. The Units issued under the Offering will be subject to a statutory hold period of four months and one day from the date of issuance. In connection with the Offering, the Company will pay eligible finders a fee in cash equal to 8% of the gross proceeds raised from persons introduced by the Finder and/or share purchase warrants equal to 8% of the total number of Units subscribed for by persons introduced by the Finder. The broker’s warrants will be exercisable to purchase an additional share at CAD 0.05 per share for a period of 24 months from the date of issue.
공시 • Sep 29Ovation Science Inc., Annual General Meeting, Nov 25, 2025Ovation Science Inc., Annual General Meeting, Nov 25, 2025.
Reported Earnings • Aug 30Second quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.009 loss in 2Q 2023)Second quarter 2024 results: CA$0.003 loss per share (improved from CA$0.009 loss in 2Q 2023). Revenue: CA$42.2k (up CA$40.2k from 2Q 2023). Net loss: CA$75.8k (loss narrowed 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.
Board Change • Aug 15Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Joan Chypyha was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Jul 23Ovation Science Inc., Annual General Meeting, Sep 20, 2024Ovation Science Inc., Annual General Meeting, Sep 20, 2024.
Reported Earnings • May 07Full year 2023 earnings released: CA$0.027 loss per share (vs CA$0.027 loss in FY 2022)Full year 2023 results: CA$0.027 loss per share (in line with FY 2022). Revenue: CA$61.9k (down 55% from FY 2022). Net loss: CA$813.1k (loss widened 2.4% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
공시 • Apr 12Ovation Science Inc. announced that it has received $0.05 million in fundingOn April 11, 2024, Ovation Science Inc closed the transaction.
공시 • Mar 21Ovation Science Inc. announced that it expects to receive CAD 0.0675 million in fundingOvation Science Inc. announced a private placement of 1,350,000 Units at a price of CAD 0.05 per Unit for a gross proceeds of CAD 67,500 on March 20, 2024. Each unit consists of one common share of the Company and one non-transferable share purchase warrant. Each warrant is exercisable to purchase an additional common share at a price of CAD 0.05 per share for a period of 24 months from closing of the private placement. The securities issued under the private placement will be subject to a hold period expiring four months and one day from the date of issuance pursuant to applicable Canadian securities laws and relevant restrictions under the securities laws of other jurisdictions where the placees may be residents.
Reported Earnings • Nov 29Third quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 3Q 2022)Third quarter 2023 results: CA$0.007 loss per share (in line with 3Q 2022). Revenue: CA$4.4k (down 87% from 3Q 2022). Net loss: CA$193.2k (loss narrowed 2.8% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
New Risk • Oct 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (78% average weekly change). Negative equity (-CA$502k). Earnings have declined by 19% per year over the past 5 years. Revenue is less than US$1m (CA$113k revenue, or US$83k). Market cap is less than US$10m (€1.09m market cap, or US$1.15m). Minor Risk Shareholders have been diluted in the past year (6.8% increase in shares outstanding).
공시 • Oct 13Ovation Science Inc. announced that it has received CAD 0.2 million in fundingOn October 12, 2023, Ovation Science Inc. closed the transaction. Net proceeds of the offering are CAD 184,000 after payment of commissions totaling CAD 16,000. The Company issued a total of 480,000 brokers warrants.
공시 • Oct 05Ovation Science Inc. announced that it expects to receive CAD 0.2 million in fundingOvation Science Inc. announced a proposed private placement of up to 4,000,000 units at a price of CAD 0.05 per unit for the gross proceeds of CAD 200,000 on October 3, 2023. Each Unit consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase an additional share at a price of CAD 0.05 per share for a two-year term. The Company will pay a commission of 8% cash and 480,000 broker warrants in connection with this offering.
Reported Earnings • Sep 03Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)Second quarter 2023 results: CA$0.009 loss per share (further deteriorated from CA$0.007 loss in 2Q 2022). Revenue: CA$2.0k (down 93% from 2Q 2022). Net loss: CA$262.0k (loss widened 22% from 2Q 2022).
공시 • Jun 21Ovation Science Inc., Annual General Meeting, Aug 22, 2023Ovation Science Inc., Annual General Meeting, Aug 22, 2023.
Reported Earnings • May 07Full year 2022 earnings released: CA$0.027 loss per share (vs CA$0.081 loss in FY 2021)Full year 2022 results: CA$0.027 loss per share (improved from CA$0.081 loss in FY 2021). Revenue: CA$138.2k (down 39% from FY 2021). Net loss: CA$794.1k (loss narrowed 67% from FY 2021).
Reported Earnings • Nov 30Third quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 3Q 2021)Third quarter 2022 results: CA$0.007 loss per share (in line with 3Q 2021). Revenue: CA$34.5k (down 1.1% from 3Q 2021). Net loss: CA$198.8k (loss narrowed 1.9% from 3Q 2021).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 28Second quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2021)Second quarter 2022 results: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2021). Revenue: CA$29.5k (down 61% from 2Q 2021). Net loss: CA$214.3k (loss widened 4.7% from 2Q 2021).
Reported Earnings • May 04Full year 2021 earnings released: CA$0.081 loss per share (vs CA$0.044 loss in FY 2020)Full year 2021 results: CA$0.081 loss per share (down from CA$0.044 loss in FY 2020). Revenue: CA$224.9k (down 70% from FY 2020). Net loss: CA$2.39m (loss widened 102% from FY 2020).
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Ian Howard was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 28Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: CA$0.007 loss per share (up from CA$0.01 loss in 3Q 2020). Revenue: CA$34.9k (down 81% from 3Q 2020). Net loss: CA$202.6k (loss narrowed 20% from 3Q 2020). Revenue was in line with analyst estimates.
Reported Earnings • Sep 02Second quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.025 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: CA$76.3k (down 24% from 2Q 2020). Net loss: CA$204.7k (loss narrowed 67% from 2Q 2020).
Reported Earnings • Jun 03First quarter 2021 earnings released: CA$0.006 loss per share (vs CA$0.005 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: CA$73.5k (down 75% from 1Q 2020). Net loss: CA$161.4k (loss widened 46% from 1Q 2020).
Reported Earnings • May 02Full year 2020 earnings released: CA$0.044 loss per share (vs CA$0.052 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: CA$750.0k (up 148% from FY 2019). Net loss: CA$1.18m (loss widened 42% from FY 2019).
Reported Earnings • Dec 02Third quarter 2020 earnings released: CA$0.01 loss per shareThe company reported a solid third quarter result with improved revenues and control over expenses, though losses increased. Third quarter 2020 results: Revenue: CA$181.0k (up 129% from 3Q 2019). Net loss: CA$253.8k (loss widened 80% from 3Q 2019).